A securities fraud class action was filed against ImmunityBio, Inc. (NASDAQ: IBRX) in the U.S. District Court for the Central District of California, Case No. 2:26-cv-03261, targeting investors who purchased IBRX securities between Jan. 19, 2026, and March 24, 2026 [1]. The complaint alleges that defendants made materially false and misleading statements and omitted material facts concerning the company's business and operations during the class period [1]. The lead plaintiff deadline is May 26, 2026 [1].
The action proceeds under the Private Securities Litigation Reform Act of 1995, the federal framework governing securities fraud class actions that requires appointment of a lead plaintiff, typically the investor with the largest financial interest in the litigation, before the case advances on the merits. The compressed two-month class period, spanning fewer than ten weeks, signals that plaintiffs' counsel has identified a specific alleged disclosure failure or corrective disclosure event, rather than asserting a broad, multi-year pattern of misrepresentation. Kessler Topaz Meltzer & Check LLP, a firm with an extensive record in shareholder litigation, filed the complaint and is soliciting class members [1].
ImmunityBio is a clinical-stage biopharmaceutical company focused on oncology and infectious disease therapies. The narrow class window and the company's development-stage profile, where material corporate milestones such as clinical trial data, regulatory submissions, or financing transactions can move share prices sharply, are consistent with a fact pattern in which a specific event is alleged to have revealed previously undisclosed information. The complaint does not, as summarized in available sources, identify the precise corrective disclosure or the individual defendants by name [1].
The case now enters its organizational phase. Potential lead plaintiffs must file motions by May 26, 2026, after which the court will evaluate competing applications and appoint lead counsel [1]. Once a lead plaintiff is in place, defendants will have an opportunity to move to dismiss under the PSLRA's heightened pleading standards, which require particularized allegations of falsity and scienter. That motion, if filed, will be the first substantive test of the complaint's viability and is likely to surface the specific statements and omissions at the center of the dispute.